Akademska digitalna zbirka SLovenije - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov konzorcija SI. Za polni dostop se PRIJAVITE.

1
zadetkov: 9
1.
  • Preoperative chemotherapy a... Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
    Curioni-Fontecedro, Alessandra; Perentes, Jean Yannis; Gelpke, Hans ... British journal of cancer, 05/2019, Letnik: 120, Številka: 10
    Journal Article
    Recenzirano
    Odprti dostop

    Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of 28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we ...
Celotno besedilo
Dostopno za: EMUNI, FIS, FZAB, GEOZS, GIS, IJS, IMTLJ, KILJ, KISLJ, MFDPS, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, SBMB, SBNM, UKNU, UL, UM, UPUK, VKSCE, ZAGLJ

PDF
2.
  • 721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors
    Gomez-Roca, Carlos; Steeghs, Neeltje; Gort, Eelke ... Journal for immunotherapy of cancer, 11/2023, Letnik: 11, Številka: Suppl 1
    Journal Article
    Recenzirano
    Odprti dostop

    BackgroundDose-limiting toxicity (DLT) due to systemic CD40 activation and peripheral target-mediated drug disposition are major challenges in clinical development of CD40 agonists. MP0317, a ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK
3.
  • Effect of MP0317, a FAP x C... Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors
    Steeghs, Neeltje; Gomez-Roca, Carlos A.; Korakis, Iphigenie ... Journal of clinical oncology, 06/2024, Letnik: 42, Številka: 16_suppl
    Journal Article
    Recenzirano

    2573 Background: Major challenges of the clinical development of CD40 agonists are toxicity due to systemic CD40 activation and peripheral target-mediated drug disposition. MP0317, a CD40 agonist ...
Celotno besedilo
4.
  • Ensovibep, a SARS‐CoV‐2 ant... Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study
    Stojcheva, Nina; Gladman, Stacy; Soergel, Marianne ... British journal of clinical pharmacology, July 2023, 2023-Jul, 2023-07-00, 20230701, Letnik: 89, Številka: 7
    Journal Article
    Recenzirano

    Aims This study aimed to assess safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of ensovibep, a designed ankyrin repeat protein antiviral being evaluated as a COVID‐19 ...
Celotno besedilo
Dostopno za: BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SAZU, SBCE, SBMB, UL, UM, UPUK
5.
  • Transcriptional control of ... Transcriptional control of O6‐methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma
    Happold, Caroline; Stojcheva, Nina; Silginer, Manuela ... Journal of neurochemistry, March 2018, 20180301, Letnik: 144, Številka: 6
    Journal Article
    Recenzirano
    Odprti dostop

    O6‐methylguanine DNA methyltransferase (MGMT) promoter methylation is a predictive biomarker for benefit from alkylating chemotherapy, specifically temozolomide (TMZ), in glioblastoma, the most ...
Celotno besedilo
Dostopno za: BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SAZU, SBCE, SBMB, UL, UM, UPUK

PDF
6.
  • Phase I study of MP0317, a ... Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors
    Gomez-Roca, Carlos A.; Steeghs, Neeltje; Gort, Eelke Hiddo ... Journal of clinical oncology, 06/2023, Letnik: 41, Številka: 16_suppl
    Journal Article
    Recenzirano

    2584 Background: CD40 is a master switch for both innate and adaptive immune systems. The clinical development of CD40 agonists has been hampered by dose-limiting toxicity (DLT) due to systemic CD40 ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK
7.
  • MicroRNA-138 promotes acqui... MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM
    Stojcheva, Nina; Schechtmann, Gennadi; Sass, Steffen ... Oncotarget, 03/2016, Letnik: 7, Številka: 11
    Journal Article
    Odprti dostop

    Glioblastoma is the most aggressive brain tumor in adults with a median survival below 12 months in population-based studies. The main reason for tumor recurrence and progression is constitutive or ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
8.
  • The Designed Ankyrin Repeat... The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study
    Kingsley, Jeff; Kumarasamy, Nagalingeswaran; Abrishamian, Luis ... Open forum infectious diseases, 06/2024, Letnik: 11, Številka: 6
    Journal Article
    Recenzirano
    Odprti dostop

    Abstract Background The coronavirus disease 2019 (COVID-19) pandemic was characterized by rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, affecting viral ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK
9.
  • 1130. Ensovibep antiviral a... 1130. Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial
    Abrishamian, Luis; Bonten, Marc; Chandra, Richa ... Open forum infectious diseases, 12/2022, Letnik: 9, Številka: Supplement_2
    Journal Article
    Recenzirano
    Odprti dostop

    Abstract Background Ensovibep is a multi-specific DARPin (designed ankyrin repeat protein) antiviral in clinical development for treatment of COVID-19. In the Phase 2 EMPATHY study, ensovibep ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK
1
zadetkov: 9

Nalaganje filtrov